IRadimed Corp
Change company Symbol lookup
Select an option...
IRMD IRadimed Corp
CMI Cummins Inc
INVH Invitation Homes Inc
OII Oceaneering International Inc
SINO Sino-Global Shipping America Ltd
MLM Martin Marietta Materials Inc
KO Coca-Cola Co
VICI VICI Properties Inc
PLT Plantronics Inc
THG Hanover Insurance Group Inc
Go

Health Care : Health Care Equipment & Supplies | Small Cap Growth
Company profile

IRADIMED CORPORATION (IRADIMED) develops, manufactures, markets and distributes Magnetic Resonance Imaging (MRI) compatible products, and provides non-magnetic intravenous (IV) infusion pump systems. The Company operates through development, manufacture and sale of MRI compatible products and IV infusion pump systems for use by hospitals and acute care facilities during MRI procedures segment. Its MRidium MRI compatible IV infusion pump system has been designed with a non-magnetic ultrasonic motor, non-ferrous part and other features in order to deliver anesthesia and other IV fluids during various MRI procedures. MRI compatible IV infusion pump system includes the 3860+ MRI compatible IV infusion pump, single-use IV tubing sets, a non-magnetic pole and a lithium battery. In addition, it offers optional upgrade systems, including the 3865 Remote Display/Control, 3861 Side Car, Dose Error Reduction System (DERS) and SpO2 monitor.

Postmarket

Last Trade
Delayed
$22.65
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--

Market Hours

Closing Price
$22.65
Day's Change
0.70 (3.19%)
Bid close
--
Ask close
--
B/A Size
--
Day's High
22.90
Day's Low
21.88
Volume
(Heavy Day)
Volume:
62,230

10-day average volume:
31,394
62,230

Propeller Health Enters Japan with Digital Health Sensor for New Enerzair(R) and Atectura(R) Breezhaler(R) Asthma Medications

8:00 am ET August 26, 2020 (BusinessWire) Print

Propeller Health today announced it will begin distributing in Japan, via a collaboration with Novartis to connect the Propeller digital health platform to Enerzair(R) and Atectura(R) Breezhaler(R), two new once-daily Novartis medications available outside the U.S. to treat uncontrolled asthma.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200826005261/en/

Patients using Enerzair(R) and Atectura(R) Breezhaler(R) to manage their uncontrolled asthma in Japan will have the option to enroll in Propeller's digital health platform to help manage their condition.

Propeller's platform works by attaching a sensor to the Enerzair(R) Breezhaler(R) or Atectura(R) Breezhaler(R) inhaler, which then delivers objective data on medication use to the Propeller app on the patient's smartphone. The app also sends the patient reminders to take their prescribed dose and keeps a record of adherence data over time. The patient can share that data with their clinician to help inform the patient's treatment plan.

"We are thrilled to bring the Propeller platform to Japan and introduce digital health for asthma to a large population of patients who can benefit from better management," said David Van Sickle, co-founder and CEO of Propeller Health. "This collaboration is an important step in improving outcomes for people with chronic respiratory disease worldwide."

Enerzair(R) Breezhaler(R) was approved in Japan on June 29 for the treatment of bronchial asthma (when combination of inhaled corticosteroids, inhaled long-acting B2-agonists, and inhaled long-acting anticholinergic agents is required). Atectura(R) Breezhaler(R) was also approved as a LABA/ICS combination asthma treatment.

In previous clinical studies unrelated to this partnership, the Propeller platform has been shown to increase asthma control by up to 63 percent,(1) increase medication adherence by up to 58 percent,(2) and reduce asthma-related emergency department visits and hospitalizations by as much as 57 percent.(3)

Propeller and Novartis first announced a collaboration to pair the Enerzair(R) Breezhaler(R) and Propeller digital health platform in Europe in July 2020.

1 Merchant RK et al. J Allergy Clin Immunol Pract 2016 2 Van Sickle D et al. Eur Respir J 2016 3 Merchant RK et al. World Allergy Org J 2018

About Propeller Health

Propeller Health is a leading digital health company dedicated to making life better for every person with chronic respiratory disease. Propeller creates products to more effectively treat chronic respiratory disease and improve clinical outcomes for patients through connectivity, analytics, and companion digital experiences. The Propeller platform is used by patients, physicians and healthcare organizations in the United States, Europe and Asia. Propeller Health is a wholly owned subsidiary of ResMed (NYSE: RMD, ASX: RMD). For more information, visit www.propellerhealth.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200826005261/en/

SOURCE: Propeller Health">

Rachel Fields
+1 630.901.8265
rachel.fields@propellerhealth.com
comtex tracking

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.